BCTX - BriaCell's Bria-IMT regimen shows clinical benefit in breast cancer patients shares up 16%

BriaCell Therapeutics (BCTX) soars 16% premarket after announcing results from clinical studies with its lead product candidate, Bria-IMT at AACR Meeting 2021.Patients were treated with the Bria-IMT regimen alone (i.e. monotherapy study) or in combination with immune checkpoint inhibitors. The Bria-IMT regimen with or without checkpoint inhibitors could induce an effective immune response and disease control in heavily pre-treated advanced breast cancer patients.Delayed Type Hypersensitivity to Bria-IMT analysis identified a group with significantly higher rates of disease control and progression-free survival ((PFS)) (8 months) in both monotherapy and combination studies suggesting a robust immune response is predictive of clinical benefit in these patients.Patients with Grade I/II tumors were more likely to respond with disease control (67%) and longer PFS.The response was more pronounced in the patients in the combination therapy study suggesting additive or synergistic effects of checkpoint inhibitors when combined with the Bria-IMT regimen.#AACR21

For further details see:

BriaCell's Bria-IMT regimen shows clinical benefit in breast cancer patients, shares up 16%